Compare SCYX & VRAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | VRAR |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 21.9M |
| IPO Year | 2014 | 2021 |
| Metric | SCYX | VRAR |
|---|---|---|
| Price | $0.63 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | $2.62 |
| AVG Volume (30 Days) | ★ 458.0K | 107.4K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,932,000.00 | ★ $9,488,209.00 |
| Revenue This Year | $167.73 | N/A |
| Revenue Next Year | $290.78 | $72.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.60 |
| 52 Week Low | $0.57 | $0.89 |
| 52 Week High | $1.49 | $7.00 |
| Indicator | SCYX | VRAR |
|---|---|---|
| Relative Strength Index (RSI) | 38.09 | 38.36 |
| Support Level | $0.63 | $0.89 |
| Resistance Level | $0.65 | $1.10 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 5.74 | 27.59 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.